Native IGF-1 exists as an FDA-approved human drug: recombinant human IGF-1, marketed as mecasermin (brand name Increlex), is approved for the treatment of growth failure in children with severe primary IGF-1 deficiency and in patients who have developed neutralizing antibodies to growth hormone
vaccine, undergoing rigorous clinical trials
Keltai, F
Electrolytes can be helpful for some GLP-1 users, especially during low-intake days, hot weather, workouts, vomiting, diarrhea, headaches, dizziness, or dose-increase weeks
Impurities and degradation byproducts from poor synthesis or poor storage
In weight loss trials, participants on the highest dose (2.4 mg) lost more than 15% of their body weight by week 48